From Policy to Scale: Regulation, Innovation and Competitiveness in European HealthTech

European Digital HealthTech Conference, organised by Luxinnovation, underscored that in Europe, and particularly in ecosystems like Luxembourg, there are no longer constraints on vision, talent, or infrastructure. The pieces are already in place.

High-performance computing, sovereign cloud capabilities, AI infrastructure, and a rapidly growing base of healthtech companies are converging around a long-standing ambition: shifting healthcare toward preventative, personalised, data-driven models.

The ecosystem is scaling fast, with hundreds of companies, thousands of jobs, and strong public-private coordination.

Already a €22.7 billion market in 2024, expected to exceed €300 billion by 2032, with 94% of EU healthcare providers investing or planning to invest in AI and 46% of vendors prioritising it as a strategic growth area. (source: European Commission, DG CNECT).

The real question is no longer whether the capacity exists.
It is whether we are structuring it correctly to deliver outcomes at scale.

As highlighted by Marco Marsella, the European Commission’s approach to health innovation is not built around a single lever, but around a dense and interdependent policy stack. HealthTech today sits at the intersection of multiple regulatory and strategic frameworks. From pharmaceutical reform and medical device regulation to the Artificial Intelligence Act and the European Health Data Space, all are combined with parallel funding instruments.

This layered architecture reflects both Europe’s strength and its complexity: health innovation is no longer a linear process but a system-level challenge, where regulatory alignment, data governance, market access, and funding mechanisms must evolve in parallel.

The implication is clear: competitiveness in HealthTech is no longer defined by technology alone, but by the ability to navigate and operationalise this policy ecosystem effectively.

From an EU digital policy and funding perspective, three signals stood out.

The shift from “innovation” to outcomes is real

The conversation has clearly moved beyond innovation for its own sake.

The most credible actors are focused on building durable, exploitable results through collaboration.

Companies are not just funding for the sake of funding.

EU programmes are not just financing tools.
They are instruments shaping markets, standards, and infrastructures.

Data is no longer a layer. It is the system

A persistent inefficiency remains:

“Why are we creating data again and again, to clean them up afterwards, again and again?”

Despite years of investment, too many initiatives still treat:
– standardisation
– interoperability
– governance

as downstream fixes rather than design principles.

The result is predictable:
duplication, delays, and underutilised AI.

Until data is structured correctly at source—FAIR, interoperable, governed—scaling AI and real-world evidence will remain constrained.

EU funding is powerful—but still misunderstood

The upside is significant:
– access to strategic networks
– exposure to regulators, industry, and patient ecosystems
– influence on emerging infrastructures (e.g. federated data spaces)
– stronger pathways to long-term value creation

But the operational reality is demanding:
– heavy pre-investment
– reimbursement-based funding
– long timelines vs startup speed
– complex consortium dynamics

And critically:
“It’s not a sales channel.”

EU projects are not about pushing products.
They are about co-developing systems, aligning stakeholders, and positioning for long-term relevance.

The discussion around AI in proposals reflects a growing maturity.

AI can accelerate drafting—but it cannot replace strategy, alignment, or intent.

“The secret… is the people.”

Strong proposals—and successful projects—are built on the right coalition, not just well-written text.

What needs to change?

Five priorities are clear:

Shift from participation → asset creation
Every project must generate reusable assets: data infrastructures, validated pathways, interoperable systems, or regulatory-grade evidence.

Build data correctly from day one
Standardisation, metadata, governance, and interoperability must be embedded at design stage.

Align funding strategy with business reality
Not every organisation should enter every consortium. Financial structure, timeline tolerance, and strategic fit must be explicit.

Strengthen the policy-to-execution layer
Europe does not lack ambition. It lacks enough actors who can translate policy into deployable systems.

Treat consortium building as a strategic capability
High-performing consortia are designed and aligned well before calls open, not assembled at the last minute.

Those aligning early with the right calls, partners, and execution models will not just participate—they will shape the next layer of European health systems.

Europe is no longer lacking direction.

The difference now lies in execution—and in who moves first with clarity.

The current EU funding landscape offers a unique window of acceleration.
Programmes such as Horizon Europe and Digital Europe Programme, and EIC funding provide powerful instruments to move from concept to scale within the current MFF cycle.

Innovation today can be deployed, tested, and scaled at a speed and with technological leverage that were not accessible even a few years ago.

Navigating this landscape efficiently is now a competitive advantage in itself.
Northglow Luxembourg grant scanning platform NorthGrantAI EU is here to help identify the right opportunities and position innovation where it can scale fastest.

The conditions are in place.
The tools are available.

The next phase belongs to those who act decisively and build at scale with the right strategy and systems in place.